Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.
Also called NCT02662569
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 986 participants
- Sponsor
- Registry
-
NCT02662569 -
2013-000723-14
-
- Other papers using this trial's data
- Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, China, Colombia, France, Russia, South Korea, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02662569. Randomized; quadruple masking; primary purpose treatment. Start 2016-04-14 (actual); primary completion 2017-12-06 (actual). Results posted on 2019-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
- Acronym
- BERSON
- Condition
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Atorvastatin
- Intervention (Other)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02662569- Content hash
5a613d99c9d652da68fad350349e36664b073008d382d81546899179118d0b5f